Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Artificial Intelligence | Research

Improve individual treatment by comparing treatment benefits: cancer artificial intelligence survival analysis system for cervical carcinoma

Authors: Jieyi Liang, Tingshan He, Hong Li, Xueqing Guo, Zhiqiao Zhang

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Purpose

The current study aimed to construct a novel cancer artificial intelligence survival analysis system for predicting the individual mortality risk curves for cervical carcinoma patients receiving different treatments.

Methods

Study dataset (n = 14,946) was downloaded from Surveillance Epidemiology and End Results database. Accelerated failure time algorithm, multi-task logistic regression algorithm, and Cox proportional hazard regression algorithm were used to develop prognostic models for cancer specific survival of cervical carcinoma patients.

Results

Multivariate Cox regression identified stage, PM, chemotherapy, Age, PT, and radiation_surgery as independent influence factors for cervical carcinoma patients. The concordance indexes of Cox model were 0.860, 0.849, and 0.848 for 12-month, 36-month, and 60-month in model dataset, whereas it were 0.881, 0.845, and 0.841 in validation dataset. The concordance indexes of accelerated failure time model were 0.861, 0.852, and 0.851 for 12-month, 36-month, and 60-month in model dataset, whereas it were 0.882, 0.847, and 0.846 in validation dataset. The concordance indexes of multi-task logistic regression model were 0.860, 0.863, and 0.861 for 12-month, 36-month, and 60-month in model dataset, whereas it were 0.880, 0.860, and 0.861 in validation dataset. Brier score indicated that these three prognostic models have good diagnostic accuracy for cervical carcinoma patients. The current research lacked independent external validation study.

Conclusion

The current study developed a novel cancer artificial intelligence survival analysis system to provide individual mortality risk predictive curves for cervical carcinoma patients based on three different artificial intelligence algorithms. Cancer artificial intelligence survival analysis system could provide mortality percentage at specific time points and explore the actual treatment benefits under different treatments in four stages, which could help patient determine the best individualized treatment. Cancer artificial intelligence survival analysis system was available at: https://​zhangzhiqiao15.​shinyapps.​io/​Tumor_​Artificial_​Intelligence_​Survival_​Analysis_​System/​.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed
2.
go back to reference Lorenz E, Strickert T, Hagen B. Radiation therapy in cervical carcinoma: fifteen years experience in a Norwegian health region. Eur J Gynaecol Oncol. 2009;30:20–4.PubMed Lorenz E, Strickert T, Hagen B. Radiation therapy in cervical carcinoma: fifteen years experience in a Norwegian health region. Eur J Gynaecol Oncol. 2009;30:20–4.PubMed
3.
go back to reference Kokawa K, Takekida S, Kamiura S, et al. The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan. Eur J Gynaecol Oncol. 2010;31:37–43.PubMed Kokawa K, Takekida S, Kamiura S, et al. The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan. Eur J Gynaecol Oncol. 2010;31:37–43.PubMed
4.
go back to reference Huang YW, Li MD, Liu FY, Li YF. Analysis of clinical efficiency of treatment for 179 geriatric women with stage I or II cervical carcinoma. Ai Zheng. 2002;21:1238–40.PubMed Huang YW, Li MD, Liu FY, Li YF. Analysis of clinical efficiency of treatment for 179 geriatric women with stage I or II cervical carcinoma. Ai Zheng. 2002;21:1238–40.PubMed
5.
go back to reference Iwata T, Miyauchi A, Suga Y, Nishio H, Nakamura M, Ohno A, Hirao N, Morisada T, Tanaka K, Ueyama H, Watari H. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470–86. Iwata T, Miyauchi A, Suga Y, Nishio H, Nakamura M, Ohno A, Hirao N, Morisada T, Tanaka K, Ueyama H, Watari H. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470–86.
6.
go back to reference Zhang X, Lv Z, Lou H. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population. BMC Cancer. 2019;19:22.PubMedPubMedCentral Zhang X, Lv Z, Lou H. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population. BMC Cancer. 2019;19:22.PubMedPubMedCentral
7.
go back to reference Zhang S, Wang X, Li Z, et al. Score for the overall survival probability of patients with first-diagnosed distantly metastatic cervical cancer: a novel nomogram-based risk assessment system. Front Oncol. 2019;9:1106.PubMedPubMedCentral Zhang S, Wang X, Li Z, et al. Score for the overall survival probability of patients with first-diagnosed distantly metastatic cervical cancer: a novel nomogram-based risk assessment system. Front Oncol. 2019;9:1106.PubMedPubMedCentral
8.
go back to reference Gulseren V, Kocaer M, Cakir I, et al. Postoperative nomogram for the prediction of disease-free survival in lymph node-negative stage I–IIA cervical cancer patients treated with radical hysterectomy. J Obstet Gynaecol. 2019;40:1–6. Gulseren V, Kocaer M, Cakir I, et al. Postoperative nomogram for the prediction of disease-free survival in lymph node-negative stage I–IIA cervical cancer patients treated with radical hysterectomy. J Obstet Gynaecol. 2019;40:1–6.
9.
go back to reference Zhou H, Li X, Zhang Y, et al. Establishing a nomogram for stage IA–IIB cervical cancer patients after complete resection. Asian Pac J Cancer Prev. 2015;16:3773–7.PubMed Zhou H, Li X, Zhang Y, et al. Establishing a nomogram for stage IA–IIB cervical cancer patients after complete resection. Asian Pac J Cancer Prev. 2015;16:3773–7.PubMed
10.
go back to reference Wang C, Yang C, Wang W, et al. A prognostic nomogram for cervical cancer after surgery from SEER database. J Cancer. 2018;9:3923–8.PubMedPubMedCentral Wang C, Yang C, Wang W, et al. A prognostic nomogram for cervical cancer after surgery from SEER database. J Cancer. 2018;9:3923–8.PubMedPubMedCentral
11.
go back to reference Zhang Z, Li J, He T, et al. The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma. Cancer Sci. 2019;110:2905–23.PubMedPubMedCentral Zhang Z, Li J, He T, et al. The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma. Cancer Sci. 2019;110:2905–23.PubMedPubMedCentral
12.
go back to reference Cheng C, Wang Q, Zhu M, et al. Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients. Cancer Cell Int. 2019;19:123.PubMedPubMedCentral Cheng C, Wang Q, Zhu M, et al. Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients. Cancer Cell Int. 2019;19:123.PubMedPubMedCentral
13.
go back to reference Zhang Z, He T, Huang L, et al. Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application. J Transl Med. 2019;17:405.PubMedPubMedCentral Zhang Z, He T, Huang L, et al. Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application. J Transl Med. 2019;17:405.PubMedPubMedCentral
14.
go back to reference Zhang Z, Li J, He T, Ding J. Bioinformatics identified 17 immune genes as prognostic biomarkers for breast cancer: application study based on artificial intelligence algorithms. Front Oncol. 2020;10:330.PubMedPubMedCentral Zhang Z, Li J, He T, Ding J. Bioinformatics identified 17 immune genes as prognostic biomarkers for breast cancer: application study based on artificial intelligence algorithms. Front Oncol. 2020;10:330.PubMedPubMedCentral
15.
go back to reference Zhang Z, Li J, He T, et al. Two predictive precision medicine tools for hepatocellular carcinoma. Cancer Cell Int. 2019;19:290.PubMedPubMedCentral Zhang Z, Li J, He T, et al. Two predictive precision medicine tools for hepatocellular carcinoma. Cancer Cell Int. 2019;19:290.PubMedPubMedCentral
16.
go back to reference Zhang Z, Liu Q, Wang P, et al. Development and internal validation of a nine-lncRNA prognostic signature for prediction of overall survival in colorectal cancer patients. PeerJ. 2018;6: e6061.PubMedPubMedCentral Zhang Z, Liu Q, Wang P, et al. Development and internal validation of a nine-lncRNA prognostic signature for prediction of overall survival in colorectal cancer patients. PeerJ. 2018;6: e6061.PubMedPubMedCentral
17.
go back to reference Zhang Z, Ouyang Y, Huang Y, et al. Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort. Cancer Cell Int. 2019;19:174.PubMedPubMedCentral Zhang Z, Ouyang Y, Huang Y, et al. Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort. Cancer Cell Int. 2019;19:174.PubMedPubMedCentral
18.
go back to reference Zhu M, Wang Q, Luo Z, et al. Development and validation of a prognostic signature for preoperative prediction of overall survival in gastric cancer patients. Onco Targets Ther. 2018;11:8711–22.PubMedPubMedCentral Zhu M, Wang Q, Luo Z, et al. Development and validation of a prognostic signature for preoperative prediction of overall survival in gastric cancer patients. Onco Targets Ther. 2018;11:8711–22.PubMedPubMedCentral
19.
go back to reference Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery. 2019;86(2):E184–92.PubMedCentral Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery. 2019;86(2):E184–92.PubMedCentral
20.
go back to reference Chang MC. Development of individual survival estimating program for cancer patients’ management. Healthc Inform Res. 2015;21:134–7.PubMedPubMedCentral Chang MC. Development of individual survival estimating program for cancer patients’ management. Healthc Inform Res. 2015;21:134–7.PubMedPubMedCentral
21.
go back to reference Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery. 2020;86:E184–92.PubMed Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery. 2020;86:E184–92.PubMed
22.
go back to reference Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazard regression model. Annu Rev Public Health. 1999;20:145–57.PubMed Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazard regression model. Annu Rev Public Health. 1999;20:145–57.PubMed
23.
go back to reference Katzman JL, Shaham U, Cloninger A, et al. DeepSurv: personalized treatment recommender system using a Cox proportional hazard deep neural network. BMC Med Res Methodol. 2018;18:24.PubMedPubMedCentral Katzman JL, Shaham U, Cloninger A, et al. DeepSurv: personalized treatment recommender system using a Cox proportional hazard deep neural network. BMC Med Res Methodol. 2018;18:24.PubMedPubMedCentral
24.
go back to reference Zare A, Hosseini M, Mahmoodi M, et al. A comparison between accelerated failure-time and cox proportional hazard models in analyzing the survival of gastric cancer patients. Iran J Public Health. 2015;44:1095–102.PubMedPubMedCentral Zare A, Hosseini M, Mahmoodi M, et al. A comparison between accelerated failure-time and cox proportional hazard models in analyzing the survival of gastric cancer patients. Iran J Public Health. 2015;44:1095–102.PubMedPubMedCentral
25.
go back to reference Alaeddini A, Hong SH. A multi-way multi-task learning approach for multinomial logistic regression*. An application in joint prediction of appointment miss-opportunities across multiple clinics. Methods Inf Med. 2017;56:294–307.PubMedPubMedCentral Alaeddini A, Hong SH. A multi-way multi-task learning approach for multinomial logistic regression*. An application in joint prediction of appointment miss-opportunities across multiple clinics. Methods Inf Med. 2017;56:294–307.PubMedPubMedCentral
26.
go back to reference Bisaso KR, Karungi SA, Kiragga A, et al. A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. BMC Med Inform Decis Mak. 2018;18:77.PubMedPubMedCentral Bisaso KR, Karungi SA, Kiragga A, et al. A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. BMC Med Inform Decis Mak. 2018;18:77.PubMedPubMedCentral
27.
go back to reference Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72:215–21.PubMed Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72:215–21.PubMed
28.
go back to reference Lee CH, Ning J, Shen Y. Analysis of restricted mean survival time for length-biased data. Biometrics. 2018;74:575–83.PubMed Lee CH, Ning J, Shen Y. Analysis of restricted mean survival time for length-biased data. Biometrics. 2018;74:575–83.PubMed
29.
go back to reference Liu M, Li H. Estimation of heterogeneous restricted mean survival time using random forest. Front Genet. 2020;11: 587378.PubMed Liu M, Li H. Estimation of heterogeneous restricted mean survival time using random forest. Front Genet. 2020;11: 587378.PubMed
30.
go back to reference Di Spazio L, Cancanelli L, Rivano M, et al. Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur Rev Med Pharmacol Sci. 2021;25:1881–9.PubMed Di Spazio L, Cancanelli L, Rivano M, et al. Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur Rev Med Pharmacol Sci. 2021;25:1881–9.PubMed
31.
go back to reference Quartagno M, Morris TP, White IR. Why restricted mean survival time methods are especially useful for non-inferiority trials. Clin Trials. 2021;18:743–5.PubMedPubMedCentral Quartagno M, Morris TP, White IR. Why restricted mean survival time methods are especially useful for non-inferiority trials. Clin Trials. 2021;18:743–5.PubMedPubMedCentral
32.
go back to reference Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350: g7594.PubMed Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350: g7594.PubMed
33.
go back to reference Lau YM, Cheung TH, Yeo W, et al. Prognostic implication of human papillomavirus types and species in cervical cancer patients undergoing primary treatment. PLoS ONE. 2015;10: e0122557.PubMedPubMedCentral Lau YM, Cheung TH, Yeo W, et al. Prognostic implication of human papillomavirus types and species in cervical cancer patients undergoing primary treatment. PLoS ONE. 2015;10: e0122557.PubMedPubMedCentral
34.
go back to reference Uppal S, Del Carmen MG, Rice LW, et al. Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer. Gynecol Oncol. 2016;142:286–92.PubMed Uppal S, Del Carmen MG, Rice LW, et al. Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer. Gynecol Oncol. 2016;142:286–92.PubMed
35.
go back to reference Hou WH, Schultheiss TE, Wong JY, et al. Surgery versus radiation treatment for high-grade neuroendocrine cancer of uterine cervix: a surveillance epidemiology and end results database analysis. Int J Gynecol Cancer. 2018;28:188–93.PubMed Hou WH, Schultheiss TE, Wong JY, et al. Surgery versus radiation treatment for high-grade neuroendocrine cancer of uterine cervix: a surveillance epidemiology and end results database analysis. Int J Gynecol Cancer. 2018;28:188–93.PubMed
37.
go back to reference Fleming ND, Frumovitz M, Schmeler KM, et al. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015;136:48–53.PubMed Fleming ND, Frumovitz M, Schmeler KM, et al. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015;136:48–53.PubMed
38.
go back to reference Yan RN, Zeng Z, Liu F, et al. Primary radical hysterectomy vs chemoradiation for IB2-IIA cervical cancer: a systematic review and meta-analysis. Medicine. 2020;99: e18738.PubMedPubMedCentral Yan RN, Zeng Z, Liu F, et al. Primary radical hysterectomy vs chemoradiation for IB2-IIA cervical cancer: a systematic review and meta-analysis. Medicine. 2020;99: e18738.PubMedPubMedCentral
39.
go back to reference Liang Y, Chai H, Liu XY, et al. Cancer survival analysis using semi-supervised learning method based on Cox and AFT models with L1/2 regularization. BMC Med Genom. 2016;9:11. Liang Y, Chai H, Liu XY, et al. Cancer survival analysis using semi-supervised learning method based on Cox and AFT models with L1/2 regularization. BMC Med Genom. 2016;9:11.
40.
go back to reference Karimi A, Delpisheh A, Sayehmiri K. Application of accelerated failure time models for breast cancer patients’ survival in Kurdistan Province of Iran. J Cancer Res Ther. 2016;12:1184–8.PubMed Karimi A, Delpisheh A, Sayehmiri K. Application of accelerated failure time models for breast cancer patients’ survival in Kurdistan Province of Iran. J Cancer Res Ther. 2016;12:1184–8.PubMed
41.
go back to reference Stankowski-Drengler TJ, Schumacher JR, Hanlon B, et al. Outcomes for patients with residual stage II/III breast cancer following neoadjuvant chemotherapy (AFT-01). Ann Surg Oncol. 2020;27:637–44.PubMedPubMedCentral Stankowski-Drengler TJ, Schumacher JR, Hanlon B, et al. Outcomes for patients with residual stage II/III breast cancer following neoadjuvant chemotherapy (AFT-01). Ann Surg Oncol. 2020;27:637–44.PubMedPubMedCentral
42.
go back to reference Talaei-Khoei A, Tavana M, Wilson JM. A predictive analytics framework for identifying patients at risk of developing multiple medical complications caused by chronic diseases. Artif Intell Med. 2019;101: 101750.PubMed Talaei-Khoei A, Tavana M, Wilson JM. A predictive analytics framework for identifying patients at risk of developing multiple medical complications caused by chronic diseases. Artif Intell Med. 2019;101: 101750.PubMed
43.
go back to reference Xia E, Mei J, Xie G, et al. Learning doctors’ medicine prescription pattern for chronic disease treatment by mining electronic health records: a multi-task learning approach. AMIA Annu Symp Proc. 2017;2017:1828–37.PubMed Xia E, Mei J, Xie G, et al. Learning doctors’ medicine prescription pattern for chronic disease treatment by mining electronic health records: a multi-task learning approach. AMIA Annu Symp Proc. 2017;2017:1828–37.PubMed
44.
go back to reference Gu W, Zhang Z, Xie X, He Y. An improved muti-task learning algorithm for analyzing cancer survival data. IEEE/ACM Trans Comput Biol Bioinform. 2019;18(2):500–11. Gu W, Zhang Z, Xie X, He Y. An improved muti-task learning algorithm for analyzing cancer survival data. IEEE/ACM Trans Comput Biol Bioinform. 2019;18(2):500–11.
Metadata
Title
Improve individual treatment by comparing treatment benefits: cancer artificial intelligence survival analysis system for cervical carcinoma
Authors
Jieyi Liang
Tingshan He
Hong Li
Xueqing Guo
Zhiqiao Zhang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03491-8

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.